EUVIMEDEUVIMED entdecken
Crossref

Chloramphenicol treatment revisited – demographics, clinical characteristics, and outcomes of hospitalized patients

Eli Ben-Chetrit, Alon Bnaya, Orit Wolfovitz Barchad, Koral Vedder, David E Katz

European Journal of Clinical Microbiology & Infectious Diseases · 2024-08 · 43 (8) · 1667-1671

DOI: 10.1007/s10096-024-04826-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 24.06.2024. Verfasst von Eli Ben-Chetrit und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shaare Zedek Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Chloramphenicol, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited literature exists on chloramphenicol's clinical use. In this retrospective, single-center case-series, we examined 183 chloramphenicol-treated and 81 piperacillin-tazobactam-treated medical patients. Chloramphenicol recipients were older, more debilitated, cognitively impaired, and penicillin allergic, while increased need for inotropics, higher leukocyte count, and higher creatinine levels were notable in the piperacillin-tazobactam group. Pneumonia was the most common indication, with no mortality difference between groups. While acknowledging its antimicrobial activity and potential benefit in specific conditions such as pneumonia, further clinical studies are needed to assess the role of chloramphenicol in the setting where other alternatives are available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChloramphenicolAnti-Bacterial AgentsHumansRetrospective StudiesMaleAgedFemaleMiddle AgedAged, 80 and overHospitalizationTreatment OutcomePiperacillin, Tazobactam Drug CombinationAdultDemography

Substanzen

ChloramphenicolAnti-Bacterial AgentsPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Department of Infectious Diseases, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Department of Internal Medicine, Shaare Zedek Medical Center, P.O.B. 3235, Jerusalem, 9103102, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Hebrew University School of Medicine, Jerusalem, Israel.
  • Department of Internal Medicine, Shaare Zedek Medical Center, P.O.B. 3235, Jerusalem, 9103102, Israel. dkatz@szmc.org.

Zitieren

APA

Ben-Chetrit, E., Bnaya, A., Barchad, O. W., Vedder, K., & Katz, D. E. (2024). Chloramphenicol treatment revisited – demographics, clinical characteristics, and outcomes of hospitalized patients. European Journal of Clinical Microbiology & Infectious Diseases, 43(8), 1667-1671. https://doi.org/10.1007/s10096-024-04826-7

Vancouver

Ben-Chetrit E, Bnaya A, Barchad OW, Vedder K, Katz DE. Chloramphenicol treatment revisited – demographics, clinical characteristics, and outcomes of hospitalized patients. European Journal of Clinical Microbiology & Infectious Diseases. 2024;43(8):1667-1671. doi:10.1007/s10096-024-04826-7

BibTeX
@article{BenChetrit2024,
  author = {Ben-Chetrit, Eli and Bnaya, Alon and Barchad, Orit Wolfovitz and Vedder, Koral and Katz, David E},
  title = {Chloramphenicol treatment revisited – demographics, clinical characteristics, and outcomes of hospitalized patients},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2024},
  volume = {43},
  number = {8},
  pages = {1667--1671},
  doi = {10.1007/s10096-024-04826-7}
}
Kostenlos starten →